Avidity Biosciences, Inc.

NasdaqGM:RNAM Stock Report

Market Cap: US$11.3b

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Avidity Biosciences Valuation

Is RNAM undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Future Cash Flow Value

  • Significantly Below Future Cash Flow Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Future Cash Flow Value

What is the Fair Price of RNAM when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Ultimate guide to DCF valuation for stock investing

Learn how to determine fair value like the best investors in the world.

Below Future Cash Flow Value: RNAM ($72.82) is trading below our estimate of future cash flow value ($303.79)

Significantly Below Future Cash Flow Value: RNAM is trading below future cash flow value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for RNAM?

Key metric: As RNAM barely has revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for RNAM. This is calculated by dividing RNAM's market cap by their current book value.
What is RNAM's PB Ratio?
PB Ratio6.7x
BookUS$1.69b
Market CapUS$11.30b

Price to Book Ratio vs Peers

How does RNAM's PB Ratio compare to its peers?

The above table shows the PB ratio for RNAM vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average9x
NBIX Neurocrine Biosciences
4x19.38%US$13.0b
BMRN BioMarin Pharmaceutical
1.9x28.86%US$11.7b
EXEL Exelixis
5x11.31%US$10.8b
IONS Ionis Pharmaceuticals
25.3x59.28%US$12.5b
RNAM Avidity Biosciences
6.7x51.98%US$11.3b

Price-To-Book vs Peers: RNAM is good value based on its Price-To-Book Ratio (6.7x) compared to the peer average (9.5x).

Historical Price to Book Ratio

Historical Price to Book Ratio compares a stock's price to the book value of it's equity over time. Higher ratios indicate that investors are willing to pay more for the stock.

Fetching historical data

Price to Book Ratio vs Industry

How does RNAM's PB Ratio compare vs other companies in the US Biotechs Industry?

53 CompaniesPrice / BookEstimated GrowthMarket Cap
XBIT XBiotech
0.4xn/aUS$71.04m
MGX Metagenomi Therapeutics
0.4x-9.30%US$66.21m
FRMM Forum Markets
0.1xn/aUS$57.23m
ACRV Acrivon Therapeutics
0.4x-0.18%US$52.38m
RNAM 6.7xIndustry Avg. 2.7xNo. of Companies79PB0246810+
53 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: RNAM is expensive based on its Price-To-Book Ratio (6.7x) compared to the US Biotechs industry average (2.7x).

Price to Book Ratio vs Fair Ratio

What is RNAM's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

RNAM PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio6.7x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate RNAM's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst RNAM forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Currentn/a
US$74.64
0%
9.15%US$96.00US$72.00n/a11
Mar ’27US$72.82
US$74.64
+2.49%
9.15%US$96.00US$72.00n/a11
Feb ’27US$72.57
US$74.64
+2.85%
9.15%US$96.00US$72.00n/a11
Jan ’27US$72.13
US$74.64
+3.47%
9.15%US$96.00US$72.00n/a11
Dec ’26US$71.35
US$74.00
+3.71%
9.93%US$96.00US$65.00n/a11
Nov ’26US$69.85
US$73.67
+5.46%
9.67%US$96.00US$65.00n/a12
Oct ’26US$43.00
US$68.11
+58.40%
16.27%US$96.00US$52.00n/a18
Sep ’26US$46.58
US$67.00
+43.84%
15.93%US$96.00US$52.00n/a18
Aug ’26US$35.92
US$66.56
+85.29%
16.00%US$96.00US$50.00n/a18
Jul ’26US$28.46
US$67.24
+136.24%
15.73%US$96.00US$50.00n/a17
Jun ’26US$30.98
US$66.79
+115.58%
16.32%US$96.00US$48.00n/a14
May ’26US$32.69
US$67.07
+105.17%
16.37%US$96.00US$48.00n/a14
Apr ’26US$26.74
US$67.07
+150.83%
16.37%US$96.00US$48.00n/a14
Mar ’26US$30.64
US$66.36
+116.59%
17.80%US$96.00US$51.00US$72.8211
Feb ’26US$32.93
US$67.91
+106.22%
16.99%US$96.00US$51.00US$72.5711
Jan ’26US$29.08
US$68.27
+134.78%
16.62%US$96.00US$51.00US$72.1311
Dec ’25US$43.03
US$68.42
+59.00%
17.95%US$96.00US$51.00US$71.3512
Nov ’25US$41.87
US$68.55
+63.71%
20.27%US$96.00US$51.00US$69.8511
Oct ’25US$48.51
US$66.09
+36.24%
21.32%US$96.00US$51.00US$43.0011
Sep ’25US$44.00
US$66.80
+51.82%
21.85%US$96.00US$51.00US$46.5810
Aug ’25US$44.57
US$61.56
+38.11%
31.12%US$96.00US$45.00US$35.929
Jul ’25US$41.28
US$61.56
+49.12%
31.12%US$96.00US$45.00US$28.469
Jun ’25US$26.86
US$45.25
+68.47%
25.12%US$66.00US$33.00US$30.988
May ’25US$25.80
US$46.71
+81.06%
28.30%US$71.00US$33.00US$32.697
Apr ’25US$26.40
US$46.71
+76.95%
28.30%US$71.00US$33.00US$26.747
Mar ’25US$20.11
US$37.50
+86.47%
48.26%US$71.00US$18.00US$30.646
US$74.64
Fair Value
2.4% undervalued intrinsic discount
11
Number of Analysts

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/02/27 03:28
End of Day Share Price 2026/02/26 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Avidity Biosciences, Inc. is covered by 15 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
William PickeringBernstein
Tazeen AhmadBofA Global Research
Eric SchmidtCantor Fitzgerald & Co.